Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) have been given an average rating of “Hold” by the twenty research firms that are currently covering the company. Five analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and ten have given a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $178.71.
Several brokerages have weighed in on ICPT. Wedbush reiterated a “buy” rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a research note on Saturday, July 9th. Cantor Fitzgerald restated a “sell” rating and issued a $60.00 target price on shares of Intercept Pharmaceuticals in a research report on Monday, August 8th. Vetr cut shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $81.50 target price for the company. in a research report on Monday, August 8th. Oppenheimer Holdings Inc. dropped their target price on shares of Intercept Pharmaceuticals from $265.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, August 5th. Finally, JMP Securities restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 18th.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 1.80% during mid-day trading on Monday, hitting $161.63. 236,478 shares of the stock traded hands. The company has a 50 day moving average price of $159.02 and a 200-day moving average price of $149.36. The stock’s market capitalization is $4.00 billion. Intercept Pharmaceuticals has a one year low of $89.76 and a one year high of $217.99.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, topping the consensus estimate of ($3.69) by $0.55. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The business earned $5.52 million during the quarter, compared to analysts’ expectations of $1.72 million. During the same quarter in the previous year, the company earned ($1.99) EPS. The business’s revenue was up 1140.4% on a year-over-year basis. Equities analysts anticipate that Intercept Pharmaceuticals will post ($16.31) earnings per share for the current fiscal year.
In related news, CEO Mark Pruzanski sold 714 shares of the stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total transaction of $103,608.54. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Lisa Bright sold 246 shares of the stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00. Following the transaction, the insider now directly owns 18,460 shares in the company, valued at $2,935,140. The disclosure for this sale can be found here. Corporate insiders own 9.20% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Fund Advisors raised its position in shares of Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock valued at $60,030,000 after buying an additional 31,289 shares in the last quarter. State Street Corp raised its position in shares of Intercept Pharmaceuticals by 27.5% in the first quarter. State Street Corp now owns 521,407 shares of the biopharmaceutical company’s stock valued at $66,990,000 after buying an additional 112,431 shares in the last quarter. Societe Generale bought a new position in shares of Intercept Pharmaceuticals during the second quarter valued at about $1,697,000. Altrinsic Global Advisors LLC raised its position in shares of Intercept Pharmaceuticals by 65.5% in the first quarter. Altrinsic Global Advisors LLC now owns 292,687 shares of the biopharmaceutical company’s stock valued at $37,601,000 after buying an additional 115,870 shares in the last quarter. Finally, Carmignac Gestion raised its position in shares of Intercept Pharmaceuticals by 19.6% in the second quarter. Carmignac Gestion now owns 1,993,592 shares of the biopharmaceutical company’s stock valued at $284,446,000 after buying an additional 326,855 shares in the last quarter. 81.86% of the stock is currently owned by institutional investors and hedge funds.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.